3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
162
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Melanoma
11
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasms
5
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Uncommon Pathological Types of Lung Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcopenia
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
NSCLC
1
Motor Activity
1
Lung Squamous Cell Carcinoma Stage IV
1
Lung Diseases, Interstitial
1
Liver Diseases
1
Kidney Neoplasms
1
Interventions
Blood Specimen Collection
5
Drug Therapy
3
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Carboplatin
2
Biopsy, Large-Core Needle
2
Biopsy
2
toripalimab
1
tislelizumab
1
taxane
1
sacituzumab govitecan
1
pembrolizumab
1
atezolizumab
1
Zoledronic Acid
1
Urine Specimen Collection
1
Prophylactic Mastectomy
1
Paracentesis
1
Neuropsychological Tests
1
Mifepristone
1
Medicine, Chinese Traditional
1
Mastectomy, Segmental
1
Magnetic Resonance Spectroscopy
1
Interviews as Topic
1
Immunotherapy
1
Immunohistochemistry
1
Gene Expression Profiling
1
Doxorubicin
1
DNA
1
Cyclophosphamide
1
Combined Modality Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Triple Negative Breast Neoplasms
×
pembrolizumab
×
Clear all
NCT05916755
2023-06-23
PORTRAIT
Vall d'Hebron Institute of Oncology
Recruiting
100 enrolled